Plasma protein biomarkers for the prediction of CSF amyloid and tau and [18F]-flutemetamol PET scan result

Plasma protein biomarkers for the prediction of CSF amyloid and tau and [18F]-flutemetamol PET scan result

<strong>Background:</strong> Blood biomarkers may aid in recruitment to clinical trials of Alzheimer’s disease (AD) modifying therapeutics by triaging potential trials participants for amyloid positron emission tomography (PET) or cerebrospinal fluid (CSF) Aβ and tau tests. <strong&g...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Westwood, S, Baird, AL, Hye, A, Ashton, NJ, Nevado-Holgado, AJ, Anand, SN, Liu, B, Newby, D, Bazenet, C, Kiddle, SJ, Ward, M, Newton, B, Desai, K, Hehir, C, Zanette, M, Galimberti, D, Parnetti, L, Lleó, A, Baker, S, Narayan, VA, Van Der Flier, WM, Scheltens, P, Teunissen, CE, Visser, PJ, Lovestone, S
Formáid:	Journal article
Foilsithe / Cruthaithe:	Frontiers Media 2018

Míreanna comhchosúla

Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [18F]-Flutemetamol PET Scan Result
de réir: Sarah Westwood, et al.
Foilsithe / Cruthaithe: (2018-12-01)

The influence of insulin resistance on CSF and plasma biomarkers of Alzheimer’s pathology
de réir: Westwood, S, et al.
Foilsithe / Cruthaithe: (2017)

New CSF biomarkers on the block
de réir: Charlotte E Teunissen, et al.
Foilsithe / Cruthaithe: (2016-09-01)

Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease
de réir: Rosha Babapour Mofrad, et al.
Foilsithe / Cruthaithe: (2019-12-01)

Determining the molecular pathways underlying the protective effect of non-steroidal anti-inflammatory drugs for Alzheimer's disease: A bioinformatics approach
de réir: Nevado-Holgado, A, et al.
Foilsithe / Cruthaithe: (2016)

CSF proteomic signature predicts progression to Alzheimer's disease dementia
de réir: Eleonora M. Vromen, et al.
Foilsithe / Cruthaithe: (2022-01-01)

Blood-based proteomic biomarkers of Alzheimer’s disease pathology
de réir: Baird, A, et al.
Foilsithe / Cruthaithe: (2015)

Determining the Molecular Pathways Underlying the Protective Effect of Non-Steroidal Anti-Inflammatory Drugs for Alzheimer's Disease: A Bioinformatics Approach
de réir: Alejo J Nevado-Holgado, et al.
Foilsithe / Cruthaithe: (2017-01-01)

CSF Proteomic Alzheimer’s Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals
de réir: Betty Marije Tijms, et al.
Foilsithe / Cruthaithe: (2021-08-01)

Establishing cutoff values for visual amyloid positivity in [18F]flutemetamol PET
de réir: Yong-Jin Park, et al.
Foilsithe / Cruthaithe: (2025-01-01)

Amyloid-Targeting PET Tracer [18F]Flutemetamol Accumulates in Atherosclerotic Plaques
de réir: Sanna Hellberg, et al.
Foilsithe / Cruthaithe: (2019-03-01)

White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation
de réir: Teunissen, C, et al.
Foilsithe / Cruthaithe: (2018)

Clinical outcomes up to 9 years after [18F]flutemetamol amyloid-PET in a symptomatic memory clinic population
de réir: Lyduine E. Collij, et al.
Foilsithe / Cruthaithe: (2023-11-01)

Clinical significance of focal ß-amyloid deposition measured by 18F-flutemetamol PET
de réir: Si Eun Kim, et al.
Foilsithe / Cruthaithe: (2020-01-01)

Comparing CSF amyloid‐beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status
de réir: Eline A. J. Willemse, et al.
Foilsithe / Cruthaithe: (2021-01-01)

Variability of CSF Alzheimer's disease biomarkers: implications for clinical practice.
de réir: Stephanie J B Vos, et al.
Foilsithe / Cruthaithe: (2014-01-01)

Thimet oligopeptidase as a potential CSF biomarker for Alzheimer's disease: A cross‐platform validation study
de réir: Yanaika S. Hok‐A‐Hin, et al.
Foilsithe / Cruthaithe: (2023-07-01)

Red blood cell indices and anaemia as causative factors for cognitive function deficits and for Alzheimer's disease
de réir: Winchester, L, et al.
Foilsithe / Cruthaithe: (2018)

Centiloid scaling for quantification of brain amyloid with [18F]flutemetamol using multiple processing methods
de réir: Mark R. Battle, et al.
Foilsithe / Cruthaithe: (2018-12-01)

White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation
de réir: Charlotte E. Teunissen, et al.
Foilsithe / Cruthaithe: (2018-03-01)

Binary classification of ¹⁸F-flutemetamol PET using machine learning: comparison with visual reads and structural MRI.
de réir: Vandenberghe, R, et al.
Foilsithe / Cruthaithe: (2013)

Early-phase 18F-FP-CIT and 18F-flutemetamol PET were significantly correlated
de réir: Young-Sil An, et al.
Foilsithe / Cruthaithe: (2021-06-01)

Temporal and anatomical distribution of 18F-flutemetamol uptake in canine brain using positron emission tomography
de réir: Taesik Yun, et al.
Foilsithe / Cruthaithe: (2020-01-01)

PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases
de réir: Juhan Reimand, et al.
Foilsithe / Cruthaithe: (2019-12-01)

Blood-based biomarker candidates of cerebral amyloid using PiB PET in non-demented elderly
de réir: Westwood, S, et al.
Foilsithe / Cruthaithe: (2016)

18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial.
de réir: Vandenberghe, R, et al.
Foilsithe / Cruthaithe: (2010)

Software compatibility analysis for quantitative measures of [18F]flutemetamol amyloid PET burden in mild cognitive impairment
de réir: Hugh G. Pemberton, et al.
Foilsithe / Cruthaithe: (2023-05-01)

Automatic lesion detection and segmentation in 18F-flutemetamol positron emission tomography images using deep learning
de réir: Chan Ju Ryu
Foilsithe / Cruthaithe: (2022-12-01)

Optimized dual-time-window protocols for quantitative [18F]flutemetamol and [18F]florbetaben PET studies
de réir: Fiona Heeman, et al.
Foilsithe / Cruthaithe: (2019-03-01)

Cross-sectional and longitudinal analyses of outdoor air pollution exposure and cognitive function in UK Biobank
de réir: Cullen, B, et al.
Foilsithe / Cruthaithe: (2018)

Commonly prescribed drugs associate with cognitive function: a cross-sectional study in UK Biobank
de réir: Nevado-Holgado, A, et al.
Foilsithe / Cruthaithe: (2016)

Identification of a possible proteomic biomarker in Parkinson’s disease: discovery and replication in blood, brain and CSF
de réir: Winchester, L, et al.
Foilsithe / Cruthaithe: (2022)

18F-flutemetamol PET/CT imaging in the diagnosis of mild cognitive impairment and Alzheimer's disease：a preliminary study
de réir: LEI Zhe, et al.
Foilsithe / Cruthaithe: (2022-07-01)

Infrequent false positive [18F]flutemetamol PET signal is resolved by combined histological assessment of neuritic and diffuse plaques
de réir: Milos D. Ikonomovic, et al.
Foilsithe / Cruthaithe: (2018-06-01)

Quantitative Evaluation of 18F-Flutemetamol PET in Patients With Cognitive Impairment and Suspected Alzheimer's Disease: A Multicenter Study
de réir: Hiroshi Matsuda, et al.
Foilsithe / Cruthaithe: (2021-01-01)

Blood based proteomic biomarkers of Alzheimer’s disease pathology
de réir: Alison Louise Baird, et al.
Foilsithe / Cruthaithe: (2015-11-01)

Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer’s disease
de réir: Carla M. Startin, et al.
Foilsithe / Cruthaithe: (2019-03-01)

Red blood cell indices and anaemia as causative factors for cognitive function deficits and for Alzheimer’s disease
de réir: Laura M. Winchester, et al.
Foilsithe / Cruthaithe: (2018-06-01)

Synaptic protein CSF levels relate to memory scores in individuals without dementia
de réir: Wesenhagen, KEJ, et al.
Foilsithe / Cruthaithe: (2025)

Synaptic protein CSF levels relate to memory scores in individuals without dementia
de réir: Kirsten E. J. Wesenhagen, et al.
Foilsithe / Cruthaithe: (2025-03-01)